Vapiprost hydrochloride is a thromboxane A2 receptor antagonist. Vapiprost inhibits the aggregation and ATP release stimulated with U-46619, collagen or arachidonic acid (AA) at an IC50 of less than 2.1×10-8 M[1].
[1]. Shuichi HORIE, et al. The Potent Inhibition of Vapiprost, a Novel Thromoboxane A2 Receptor Antagonist, on the Secondary Aggregation and ATP Release of Human Platelets.
















